In August 2025, the founder and chief executive officer (CEO) of the pharmaceutical supply chain start-up Defense Operations & Engineering Solutions Inc. (DOES), faced mounting pressure as ethics and company survival collided. DOES was founded with the aim of reducing US dependence on overseas suppliers. The company developed Tech 2.0, an artificial intelligence–enabled platform for safer, more personalized drug manufacturing. Yet supplier violations, environmental concerns, and incomplete audits threatened its credibility. With just US$0.8 million left and investors demanding rapid progress, the CEO considered three options: partner with a low-cost but non-compliant supplier, delay production to achieve full compliance, or disclose all risks to investors and regulators at the cost of losing short-term funding.
看看哪些人也有訂購？